Cargando…
Tumor PD-L1 Expression and Clinical Outcomes in Advanced-stage Non-Small Cell Lung Cancer Patients Treated with Nivolumab or Pembrolizumab: Real-World Data in Taiwan
Background: Immunotherapy that targets programmed death protein-1 (PD-1) provides improved treatment efficacy and survival in patients with metastatic non-small cell lung cancer (NSCLC), especially those with high tumor expression of PD-L1. However, data on this treatment are mostly from clinical tr...
Autores principales: | Lin, Shu-Yung, Yang, Ching-Yao, Liao, Bin-Chi, Ho, Chao-Chi, Liao, Wei-Yu, Chen, Kuan-Yu, Tsai, Tzu-Hsiu, Hsu, Chia-Lin, Hsu, Wei-Hsun, Su, Kang-Yi, Chang, Yih-Leong, Lee, Jih-Hsiang, Lin, Chia-Chi, Shih, Jin-Yuan, Yang, James Chih-Hsin, Yu, Chong-Jen |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Ivyspring International Publisher
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5968770/ https://www.ncbi.nlm.nih.gov/pubmed/29805708 http://dx.doi.org/10.7150/jca.24985 |
Ejemplares similares
-
Pulmonary pleomorphic carcinoma with pembrolizumab monotherapy
por: Chang, Hao‐Chun, et al.
Publicado: (2020) -
Serial Plasma Cell-Free Circulating Tumor DNA Tests Identify Genomic Alterations for Early Prediction of Osimertinib Treatment Outcome in EGFR T790M–Positive NSCLC
por: Liao, Bin-Chi, et al.
Publicado: (2020) -
Real-World Comparative Effectiveness of Nivolumab versus Pembrolizumab in Patients with Unresectable Hepatocellular Carcinoma
por: Kuo, Hsin-Yu, et al.
Publicado: (2022) -
Real-world treatment patterns and outcomes among patients with advanced non-small-cell lung cancer with spindle cell and/or giant cell carcinoma
por: Chang, Chia-Ling, et al.
Publicado: (2022) -
Association of pre-ESRD care education with patient outcomes in a 10-year longitudinal study of patients with CKD stages 3–5 in Taiwan
por: Chou, Chu-Lin, et al.
Publicado: (2021)